EDWIN TORRES: Open Payments
NPI 1053715243 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$16,856 in 67 payments from 11 companies in 2025. Trend: 2023 $8,493 · 2024 $19,140 · 2025 $16,856
Consulting: $6,683Speaker / faculty: $6,275Food & beverage: $2,142Travel & lodging: $1,757
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 24 | $9,096 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $5,368 |
| Corcept Therapeutics | 9 | $1,208 |
| Lilly USA, LLC | 2 | $704 |
| Xeris Pharmaceuticals, Inc. | 6 | $235 |
| AstraZeneca Pharmaceuticals LP | 6 | $112 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Insulet Corporation | 1 | $22 |
Products named: Ozempic, JARDIANCE, Korlym, RECORLEV, Rybelsus, FARXIGA, WAINUA, LEQVIO.
Industry payments across NY — which companies pay providers there.
